YOLFTbeta
Tela Bio Inc

Tela Bio Inc

TELA · NASDAQ · Healthcare / Medical Devices

0.8201USD-0.04 (-4.64%)

Price History

Full chart

Market Stats

Previous Close0.86
Open0.82
Day Range0.76 – 0.8356
52-Week Range0.501 – 1.60
Volume129.18K
Market Cap55.53M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.75
Dividend Yield0.00%
Beta1.36
50-Day Avg0.8561
200-Day Avg0.8655

About

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene, polyglycolic acid, and polylactic-co-glycolic acid designed to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

Company Details

  • SectorHealthcare
  • IndustryMedical Devices
  • CEOMr. Jeffrey Blizard
  • Employees218
  • Headquarters1 Great Valley Parkway, Malvern, PA, United States, 19355, USA
  • Websitehttps://www.telabio.com

Leadership

  • Mr. Jeffrey BlizardPresident · b. 1969
  • Ms. Megan SmeykalVP, Corporate Controller, Chief Accounting Officer & Principal Accounting Officer · b. 1976
  • Mr. Paul TalmoChief Technology Officer · b. 1967
  • Mr. D. Taylor OcasioGeneral Counsel & Corporate Secretary
  • Mr. Jim HagenSenior VP of Strategic Commercial Operations & Marketing
  • Ms. Jennifer Lou ArmstrongSenior Vice President of Human Resources · b. 1970
  • Mr. Gregory A. FirestoneChief Business Officer · b. 1959
  • Mr. Michael LeonardSenior Vice President of Technical Operations
  • Dr. Howard N. LangsteinChief Medical Officer · b. 1959
  • Louisa SmithInvestor Relations Contact Officer

Financials

Income Statement

Currency: USD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue4.25M8.27M15.45M18.21M29.46M41.42M58.45M69.30M80.28M
Growth (%)-+94.91%+86.68%+17.91%+61.77%+40.58%+41.13%+18.56%+15.84%
Cost of Revenue1.71M5.33M6.17M6.98M10.65M14.37M18.34M22.81M25.93M
Gross Profit2.53M2.94M9.27M11.23M18.81M27.04M40.11M46.49M54.34M
Gross Margin59.65%35.56%60.03%61.68%63.85%65.30%68.62%67.08%67.69%
Operating Expense19.46M20.72M28.43M36.51M48.26M66.05M84.19M80.60M88.10M
Operating Income-16.92M-17.78M-19.16M-25.27M-29.45M-39.01M-44.08M-34.12M-33.76M
Operating Margin-398.68%-214.91%-124.06%-138.77%-99.96%-94.18%-75.40%-49.23%-42.05%
EBITDA-16.02M-18.04M-18.23M-24.70M-29.14M-39.06M-40.63M-31.68M-32.35M
EBITDA Margin-377.27%-218.06%-118.05%-135.64%-98.92%-94.30%-69.51%-45.72%-40.29%
Net Income-21.33M-21.09M-22.43M-28.79M-33.28M-44.30M-46.66M-37.84M-38.83M
Net Income Margin-502.57%-254.92%-145.18%-158.10%-112.94%-106.95%-79.83%-54.60%-48.37%
R&D5.79M4.34M4.15M4.25M6.74M8.94M9.62M8.81M9.22M
R&D as % of Total Revenue136.30%52.44%26.87%23.36%22.89%21.58%16.46%12.72%11.49%
Interest Expense4.56M1.80M3.61M3.56M3.60M4.05M5.22M5.29M5.25M
Interest Expense % of Total Revenue107.37%21.78%23.37%19.57%12.21%9.78%8.94%7.63%6.53%

Balance Sheet

Currency: USD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets15.53M27.23M67.92M86.46M62.54M67.86M78.05M87.33M81.42M
Total Liabilities123.70M165.09M36.96M37.43M42.45M53.55M59.17M58.87M75.11M
Total Equity-108.17M-137.86M30.96M49.03M20.10M14.30M18.88M28.46M6.31M
Cash11.35M17.28M45.30M74.39M43.93M42.02M46.73M52.67M50.84M
Total Debt6.21M29.73M30.24M30.83M31.49M40.26M42.77M43.06M55.65M
Net Debt-6.83M12.46M-15.06M-43.57M-12.44M-2.10M-3.96M-9.61M4.81M

Cash Flow

Currency: USD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-16.37M-19.92M-25.52M-24.46M-30.43M-40.75M-40.86M-41.59M-28.22M
Investing Cash Flow-101.00K-1.56M-11.98M9.12M-627.00K-1.87M-599.00K4.45M846.00K
Financing Cash Flow26.34M27.41M65.53M44.41M585.00K40.85M46.27M43.06M25.75M
Capital Expenditure114.00K1.56M2.70M167.00K627.00K1.87M611.00K989.00K448.00K
Free Cash Flow-16.48M-21.49M-28.22M-24.62M-31.06M-42.62M-41.47M-42.58M-28.67M
FCF to OCF100.70%107.84%110.57%100.68%102.06%104.59%101.50%102.38%101.59%

Earnings

Report DateAug 28, 2019Dec 18, 2019Mar 27, 2020May 12, 2020Aug 12, 2020Nov 11, 2020Mar 24, 2021May 13, 2021Aug 11, 2021Nov 10, 2021Mar 21, 2022May 10, 2022Aug 10, 2022Nov 9, 2022Mar 21, 2023May 11, 2023Aug 9, 2023Nov 9, 2023Mar 21, 2024May 10, 2024Aug 12, 2024Nov 7, 2024Mar 19, 2025May 8, 2025Aug 11, 2025Nov 13, 2025Mar 24, 2026May 7, 2026Aug 10, 2026Nov 12, 2026
EPS Estimate-0.58-0.45-0.59-0.56-0.59-0.48-0.49-0.48-0.52-0.52-0.55-0.56-0.62-0.56-0.54-0.56-0.52-0.27-0.43-0.51-0.47-0.42-0.22-0.21-0.18-0.20-0.18-0.15-0.17-0.19
EPS Actual-0.47-0.59-0.57-0.63-0.53-0.53-0.54-0.56-0.57-0.57-0.59-0.75-0.79-0.64-0.52-0.63-0.46-0.45-0.53-0.54-0.51-0.42-0.23-0.25-0.22-0.19-0.17-0.21-0.20-
Surprise18.97%-31.11%3.39%-12.50%10.17%-10.42%-10.20%-16.67%-9.62%-9.62%-7.27%-33.93%-27.42%-14.29%3.70%-12.50%11.54%-66.67%-23.26%-5.88%-8.51%0.00%-3.60%-19.05%-22.22%5.00%5.56%-39.86%-17.65%-
Timing-Pre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hours

Key Statistics & Ratios

Market Cap55.53M
Enterprise Value84.87M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.69
Price / Book7.30
EPS-0.75
Book Value-0.354
Revenue (TTM)79.91M
Gross Profit (TTM)54.57M
EBITDA-33.01M
Profit Margin-51.53%
Operating Margin-48.12%
Return on Equity-616.62%
Return on Assets-33.40%
Shares Outstanding45.14M
Shares Float21.47M
Beta1.36
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 5 analystsTarget 2.08
  • Strong Buy
    3
  • Buy
    1
  • Hold
    1

Ownership Breakdown

Institutions
63.29%
Insiders
7.11%
Retail / Other
29.60%

Top Institutional Holders

  • Essex Woodlands Health Ventures
    7.71M17.18%
  • Nantahala Capital Management, LLC
    5.14M11.46%
  • Stonepine Capital Management Llc
    2.62M5.83%
  • SILVERARC CAPITAL MANAGEMENT, LLC
    2.26M5.03%
  • Vanguard Capital Management, LLC
    1.54M3.43%
  • Dafna Capital Management LLC
    1.44M3.21%
  • Perkins Capital Management Inc
    1.42M3.16%
  • UBS Group AG
    1.06M2.36%
  • Citigroup Inc
    750.00K1.67%
  • Sio Capital Management, LLC
    636.30K1.42%
  • BlackRock Inc
    465.81K1.04%
  • WEALTHTRUST AXIOM LLC
    457.73K1.02%
  • Geode Capital Management, LLC
    455.06K1.01%
  • Vanguard Fiduciary Trust Co
    211.66K0.47%
  • Northern Trust Corp
    174.40K0.39%
  • UP STRATEGIC WEALTH INVESTMENT ADVISORS LLC
    99.89K0.22%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    1.15M2.56%
  • Fidelity Extended Market Index
    188.40K0.42%
  • Jacob Small Cap Growth Investor
    81.00K0.18%
  • Jacob Discovery Fd Instl
    79.78K0.18%